

COVID-19 Impact on Drug Supply

5:00 - 6:30 PM (Pacific Daylight Time), May 9 (Saturday), 2020 | Online through Zoom

Registration (free) and webinar requirements:

- Real full name and working email are required for registration
- Registration is required for attending online due to the limitation on the number of attendees
- Check your spam box if you do not see the registration notification with the webinar link and ID after you register
- Do not share the meeting access with others
- No screenshot, photography and recording permitted during this event

Registration link:

https://us02web.zoom.us/webinar/register/WN_KKHCnEsbQoyeFUm2UWORaw

Agenda:

- 16:50 SABPA Slideshow
- 17:00 Welcome to SABPA COVID19 special webinar (Yinghong Gao, Host, SABPA)
- 17:05 **COVID-19 Impact on the Development and Production of Pharmaceuticals** (Gerald J. Yakatan; Host: Yinghong Gao)
- 17:35 **Emergency Drug Supply for COVID-19, Hydroxychloroquine As a Case Study** (Tony Zhang; Co-host: Xiangming Fang)
- 18:05 Q&A (Moderators: Pengyu Yang and Feng Yang, SABPA)
- 18:30 Adjourn

Featured Speakers:



Gerald J. Yakatan, Ph.D.
Chairman & CEO
IRISYS, LLC



Tony Zhang, Ph.D.
Cofounder & CEO
Tyligand Bioscience

Event Organizers:

SABPA COVID-19 Online Event Task Force:

Andrew Wang, Guang Chen (lead organizer), Feng Yang, Hua Gong, Peter Huang, Rong Xu, Sean Zeng, Weixuan Chen, Xiangming Fan, Yan-Bo Yang

SABPA Webinar Task Force:

Andrew Wang (lead organizer), Guang Chen, Feng Yang, Pengyu Yang, Peter Huang, Peter Zhu, Rong Xu, Shuangwei Li, Xuefeng Zhu

Contact: sabpaecorner@gmail.com

Sino-American Biotechnology and Pharmaceutical Professional Association (SABPA)

SABPA is a 501(c)(3) nonprofit organization founded in early 2002 by professionals and scholars from the Chinese community in San Diego. In 2005, the organization expanded to Orange County and Los Angeles. SABPA has more than 3500 members who are scholars, professionals and entrepreneurs in the biotech and pharmaceutical industry in Southern California. SABPA is a grassroots organization managed and operated by volunteers throughout the entire organizational construct. In this volunteer-based organization, team cohesion and collaboration play vital roles that have enabled SABPA to grow, excel and succeed with its unique identity. With this identity SABPA has created a strong foundation and established a common ground to fulfill its missions and is continuously building up the collective power and synergy among its members and collaborators.



COVID-19 Impact on Drug Supply

5:00 - 6:30 PM (Pacific Daylight Time), May 9 (Saturday), 2020 | Online through Zoom

Featured Speakers:



Gerald J. Yakatan, PhD
Chairman & CEO
IRISYS, LLC

Gerald J. Yakatan, Ph.D. is a serial entrepreneur who has been a founder of multiple companies in the pharmaceutical R&D arena and currently serves as Chairman & CEO of both IriSys, LLC and Hangzhou Yagadol Pharmaceutical Technology Co., Ltd. He served as President & CEO of Avanir Pharmaceuticals where he led development efforts resulting in the NDA submission for Nuedexta® and was responsible for the development, regulatory approval and commercialization of Abreva®. Dr. Yakatan has also served as Pharmaceutics Chair at University of Texas at Austin; VP for Product Development Worldwide at Warner Lambert/Parke Davis; and Founder and CEO at Tanabe Research Labs, USA. He has served on the Boards of numerous not-for-profit organizations and received distinguished alumnus awards from Temple University and from the University of Florida.



Tony Zhang, Ph.D.
Cofounder & CEO
Tyligand Bioscience

Tony Zhang, Ph.D. is a cofounder and CEO of Tyligand Bioscience, a Shanghai based biotech focused on the discovery and development of small molecule therapeutics for oncology and autoimmune diseases. He has a BS degree from Shandong University and a PhD degree in chemistry from Purdue University. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia.

Dr. Zhang has led multi-disciplined teams in drug discovery and development across several therapeutic areas, and has published extensively in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is the inventor for 27 patents and many commercial manufacturing processes. He is a member of the editorial advisory board for the *Organic Process Research and Development* (ACS) and *Pharmaceutical Fronts* (Thieme). Dr. Zhang has also served as the chairman (2010-2011) of Bayhelix.

